Subscribe to MDT Magazine News

Blood simple circuitry for cyborgs

March 30, 2011 5:40 am | by EurekAlert | Comments

(Inderscience Publishers) Could electronic components made from human blood be the key to creating cyborg interfaces? Circuitry that links human tissues and nerve cells directly to an electronic device, such as a robotic limb or artificial eye might one day be possible thanks to...

Yale partners with Gilead Sciences in potential $100M cancer deal

March 30, 2011 5:39 am | by Mass High Tech: The Journal of New England Technology | Comments

The Yale School of Medicine at Yale University in New Haven, Conn., has entered into a long-term research partnership on cancer therapies with Gilead Sciences Inc. of California which could bring up to $100 million to the school.

Pradaxa (dabigatran etexilate mesylate) Capsules: Special Storage and Handling Requirements

March 30, 2011 5:39 am | by U.S. Food & Drug Administration | Comments

Potential for product breakdown and loss of potency if not dispensed and stored in the original bottle or blister package.


Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies

March 30, 2011 5:36 am | by Bio-Medicine.Org | Comments

RANCHO CORDOVA, Calif., March 30, 2011 /- ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier of innovative products and services that process and store adult stem cells, said today that Nanshan Memorial Medical Institute (Nanshan), a leading regenerative medicine company, will be...


Vertex CF drug candidate shows promising results

March 30, 2011 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Vertex Pharmaceuticals has announced additional positive results for its experimental therapy for Cystic Fibrosis, called VX-770, which found lung function improved by 17.4 percent in children between 6 and 11 with a specific type of CF.

Mucus: Fighting the war against pollutants

March 30, 2011 5:35 am | by EurekAlert | Comments

(American Friends of Tel Aviv University) New Tel Aviv University research has found that mucus, which was thought to protect our bodies against harmful pollutants, in fact may leave our bodies more vulnerable to them. But the discovery may prove useful in enabling some drugs to enter...

Alexion gets board OK for stock 2-1 split

March 30, 2011 4:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Alexion Pharmaceuticals Inc. has won approval from its board of directors for a two-for-one stock split, which if approved by shareholders would double the number of issued common stock shares from 145 million to 290 million.

Biodel Announces Appointment of Dr. Brian J.G. Pereira as Board Chairman; Dr. Charles A. Sanders to Remain on Board

March 30, 2011 3:38 am | by Bio-Medicine.Org | Comments

DANBURY, Conn., March 30, 2011 /- Biodel Inc. (Nasdaq: BIOD ) announced today the appointment of Dr. Brian J.G. Pereira as board chairman effective immediately.  Dr. Pereira has served on the board since November 2007.  Dr. Charles A. Sanders, who served as chairman since March...


Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes

March 30, 2011 3:38 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., March 30, 2011 /- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated...

TOPICS: is Your Number One Choice for Affordable Medications

March 30, 2011 3:37 am | by Bio-Medicine.Org | Comments

LONG ISLAND CITY, N.Y., March 30, 2011 /- Everyone knows where to look for the medications that you might have a need for one day. Online pharma shops have proven to be a reliable source for medication but how can you be sure that you are buying from the right generic Viagra merchant?...


Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease

March 30, 2011 3:37 am | by Bio-Medicine.Org | Comments

OSAKA, Japan and NEW YORK, March 30, 2011 /- Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR...


Winner Medical CEO Awarded and Appointed Position by CNITA

March 30, 2011 3:37 am | by Bio-Medicine.Org | Comments

SHENZHEN, China, March 30, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN ), ("Winner Medical") a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that Mr....


Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting

March 30, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN MATEO, Calif., March 30, 2011 /- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming cenderitide presentation taking place at the American College of Cardiology...


Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference

March 30, 2011 3:35 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., March 30, 2011 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at Needham's 10th Annual Healthcare Conference on Wednesday, April 06, 2011 at 10:40 a.m. ET at the New...


Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting

March 29, 2011 10:33 pm | by Bio-Medicine.Org | Comments

LONDON, March 30, 2011 /- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have...


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.